New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
10:00 EDTVC, PKD, DNOW, HP, GNC, BAS, AVG, SLB, PBFX, MNST, HAL, EXAS, ALQA, ROSG, ORCL, HERO, GTT, ATW, AIRMOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AVG Technologies (AVG) initiated with an In-Line at Imperial Capital... Air Methods (AIRM) initiated with a Buy at KeyBanc... Alliqua (ALQA) initiated with a Buy at Ascendiant... Atwood Oceanics (ATW) initiated with a Neutral at Macquarie... Basic Energy (BAS) initiated with a Neutral at Macquarie... Exact Sciences (EXAS) initiated with a Buy at Goldman... GNC Holdings (GNC) initiated with a Buy at BofA/Merrill... GTT Communications (GTT) initiated with an Outperform at Pacific Crest... Halliburton (HAL) initiated with an Outperform at Macquarie... Helmerich & Payne (HP) initiated with a Neutral at Macquarie... Hercules Offshore (HERO) initiated with an Outperform at Macquarie... Monster Beverage (MNST) initiated with an Outperform at Credit Suisse... NOW Inc. (DNOW) initiated with a Positive at Susquehanna... Oracle (ORCL) initiated with a Buy at Maxim... PBF Logistics (PBFX) initiated with a Market Perform at Wells Fargo... Parker Drilling (PKD) initiated with an Outperform at Macquarie... Rosetta Genomics (ROSG) initiated with an Outperform at Barrington... Schlumberger (SLB) initiated with an Outperform at Macquarie... Visteon (VC) initiated with a Buy at Gabelli.
News For AVG;AIRM;ALQA;BAS;ATW;EXAS;GNC;GTT;HAL;HP;HERO;MNST;DNOW;ORCL;PBFX;PKD;ROSG;SLB;VC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
January 13, 2015
10:00 EDTMNSTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:03 EDTSLBSchlumberger January volatility increases into Q4 and outlook
Schlumberger January call option implied volatility is at 70, February is at 41, May is at 33; compared to its 26-week average of 20, suggesting large near term price movement into the expected release of Q4 results on January 16.
08:23 EDTMNSTMonster Beverage volatility elevated into investor meeting
Monster Beverage January call option implied volatility is at 49, February is at 34, March is at 36; compared to its 26-week average of 30 according to Track Data, suggesting larger near term price movement into a company hosted investor meeting today.
07:41 EDTMNSTWells downgrades Monster Beverage on valuation
Subscribe for More Information
07:30 EDTVCDeutsche Bank to hold a conference
Subscribe for More Information
07:13 EDTMNSTMonster Beverage price target raised to $130 from $115 at Stifel
Subscribe for More Information
06:25 EDTORCLOracle settles legal dispute with Alibaba Health, WSJ reports
Subscribe for More Information
05:51 EDTMNSTMonster Beverage downgraded to Market Perform from Outperform at Wells Fargo
Subscribe for More Information
January 12, 2015
10:23 EDTORCLSAP jumps 3.5% after resuming trade following Q4 report
Subscribe for More Information
10:00 EDTALQAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTSLBOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:34 EDTATWAtwood Oceanics awarded contract for Atwood Mako
Atwood Oceanics announced that one of its subsidiaries has entered into an agreement to provide drilling services with the jackup rig Atwood Mako. The contract will be performed in Southeast Asia at an operating day rate of $155,000 for a minimum term of 70 days, and it includes a priced option for an additional term. The Atwood Mako is presently working offshore Malaysia and is expected to mobilize to its new location in late March, in direct continuation of its current program.
09:03 EDTEXASExact Sciences provides update on Cologuard's early launch trajectory
Subscribe for More Information
08:17 EDTROSGRosetta Genomics sees 2H14 revenue to be 40% above 1H14
Rosetta Genomics announces the posting of a Letter to Shareholders from President and CEO Kenneth Berlin to investors, in which he stated in part: "Throughout 2014 we made significant progress advancing our three key areas for growth: current product sales, new product development and third-party collaborations...We expect revenue for the second half of 2014 to be approximately 40% higher compared with the first half of 2014, and to be more than three times the revenue we recorded in the second half of 2013. While we are still in the early stages of our full commercialization efforts and these increases are off a modest base, the growth and trends demonstrate that our strategy and marketing programs are bearing fruit as we continue to progress our microRNA-based solutions for oncology...We remain vigilant in continuing to build and strengthen our intellectual property, and are pleased to have added three U.S. patents to our growing portfolio during 2014. As a result we now have 39 issued patents, including 35 in the U.S. In addition we have 49 patent applications pending, of which 28 are in the U.S. These issued patents and applications protect the specific microRNAs used in our products and cover composition of matter, diagnostic applications, therapeutic applications and discovery process applications for microRNAs in humans...We are very pleased with the progress we have made and expect 2015 to be an exciting year of growth and accomplishments as we advance our strategic plan in pursuit of our mission to be the pioneering force in microRNA-based personalized medicine to the benefit of patients worldwide." One revenue estimate $1.14M.
07:35 EDTORCLNational Retail Federation to hold a trade show
Subscribe for More Information
07:17 EDTEXASJPMorgan to hold a conference
Subscribe for More Information
07:02 EDTALQAAlliqua initiated with an Outperform at Northland
Subscribe for More Information
06:43 EDTORCLKurian seen by some as successor to Oracle's Ellison, Reuters says
Subscribe for More Information
06:12 EDTBASBasic Energy reports Dec. well servicing rig count unchanged at 421
Subscribe for More Information
05:51 EDTSLBSchlumberger downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Schlumberger to Neutral from Buy saying it now expects global exploration and production spending to be down about 15% in 2015, pressuring the company's earnings. Goldman cut its price target for shares to $76 from $90. Shares of the drilling servicer closed Friday down $1.48 to $81.22.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use